GEBBIA, Nicolo'
 Distribuzione geografica
Continente #
NA - Nord America 12.941
EU - Europa 7.510
AS - Asia 5.803
SA - Sud America 855
AF - Africa 159
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 8
Totale 27.290
Nazione #
US - Stati Uniti d'America 12.766
SG - Singapore 2.110
RU - Federazione Russa 1.842
CN - Cina 1.542
IT - Italia 1.140
FI - Finlandia 964
DE - Germania 900
UA - Ucraina 830
BR - Brasile 691
HK - Hong Kong 603
VN - Vietnam 511
GB - Regno Unito 355
PL - Polonia 343
IE - Irlanda 279
FR - Francia 268
SE - Svezia 248
JP - Giappone 232
KR - Corea 147
IN - India 143
BD - Bangladesh 94
CA - Canada 82
AR - Argentina 69
IQ - Iraq 68
RO - Romania 63
NL - Olanda 59
MX - Messico 56
TR - Turchia 55
BE - Belgio 48
ES - Italia 41
CI - Costa d'Avorio 39
ZA - Sudafrica 35
IR - Iran 29
UZ - Uzbekistan 29
PK - Pakistan 24
MA - Marocco 23
PH - Filippine 23
AT - Austria 22
MY - Malesia 21
VE - Venezuela 21
CZ - Repubblica Ceca 19
SA - Arabia Saudita 19
AE - Emirati Arabi Uniti 18
ID - Indonesia 18
GR - Grecia 16
JO - Giordania 16
CH - Svizzera 15
CO - Colombia 15
EC - Ecuador 15
NP - Nepal 15
LT - Lituania 14
CL - Cile 13
AZ - Azerbaigian 11
EG - Egitto 11
KE - Kenya 11
KZ - Kazakistan 11
PY - Paraguay 11
TN - Tunisia 11
AU - Australia 10
JM - Giamaica 9
LB - Libano 9
AL - Albania 8
BG - Bulgaria 8
EU - Europa 8
DZ - Algeria 7
HN - Honduras 7
IL - Israele 7
PE - Perù 7
BO - Bolivia 6
ET - Etiopia 6
SY - Repubblica araba siriana 6
TW - Taiwan 6
UY - Uruguay 6
BY - Bielorussia 5
PA - Panama 5
BH - Bahrain 4
DO - Repubblica Dominicana 4
KG - Kirghizistan 4
MD - Moldavia 4
NZ - Nuova Zelanda 4
OM - Oman 4
CR - Costa Rica 3
GA - Gabon 3
GE - Georgia 3
MN - Mongolia 3
PT - Portogallo 3
SN - Senegal 3
SV - El Salvador 3
TH - Thailandia 3
AO - Angola 2
CG - Congo 2
HR - Croazia 2
HU - Ungheria 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LY - Libia 2
MM - Myanmar 2
NO - Norvegia 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
Totale 27.266
Città #
Ashburn 1.603
Singapore 1.382
Fairfield 1.243
Chandler 847
Woodbridge 721
San Jose 627
Wilmington 612
Hong Kong 589
Houston 573
Ann Arbor 539
Seattle 502
Jacksonville 424
Cambridge 387
Moscow 355
Dallas 301
Zgierz 286
Dublin 273
Beijing 254
Des Moines 244
Santa Clara 240
Palermo 227
Tokyo 224
Frankfurt am Main 219
Medford 219
Los Angeles 191
New York 186
Ho Chi Minh City 161
Nanjing 151
The Dalles 150
Princeton 145
Altamura 144
Council Bluffs 144
Hefei 127
Lauterbourg 127
Hanoi 126
Lawrence 105
Tulsa 102
Boardman 97
Helsinki 96
Buffalo 93
San Diego 81
Chicago 75
Dearborn 74
Milan 68
São Paulo 62
Orem 55
Ludwigshafen am Rhein 52
Tianjin 51
Jinan 49
Seoul 49
Shenyang 49
Brussels 48
Nanchang 46
Seongnam 45
Hebei 44
London 43
Munich 43
Changsha 42
Columbus 40
Abidjan 39
San Mateo 39
Guangzhou 35
Atlanta 34
Saint Petersburg 31
Jiaxing 30
Nuremberg 30
Amsterdam 29
Warsaw 29
Phoenix 28
Poplar 28
Chennai 27
Montreal 27
Baghdad 26
Kumar 26
Kitzingen 24
Zhengzhou 24
City of London 23
Da Nang 23
Rome 23
Stockholm 22
Denver 21
Rio de Janeiro 21
Toronto 21
Venice 21
Falls Church 20
Tehran 20
Brasília 19
Bremen 19
Brooklyn 19
Haiphong 19
Johannesburg 19
Manchester 19
Ningbo 18
San Paolo di Civitate 17
Tashkent 17
Verona 17
Cardiff 16
Mumbai 16
Washington 16
Amman 15
Totale 17.019
Nome #
4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily). 407
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment 364
Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus. 361
Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-inducing activity in HL60 and in MDR Cell lines 355
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients 313
Stilbene-based anticancer agents: Resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism. 310
Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells 299
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer 297
Anti-endothelin drugs in solid tumors 296
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features 289
A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers 282
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. 281
Studies on the apoptotic activity of natural and synthetic retinoids: discovery of a new class of synthetic terphenyls that potently support cell growth and inhibit apoptosis in neuronal and HL-60 cells 277
BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses. 276
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma 274
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells 271
Overexpression of cyclin D1 and interaction between p27(Kip1) and tumour thickness predict lymph node metastases occurrence in lower lip squamous cell carcinoma 270
I tumori della mammella e/o dell’ovaio di tipo eredofamiliare: strategie di prevenzione nelle donne ad alto rischio 270
Cathepsin D expression levels in nongynecological solid tumors: Clinical and therapeutic implications 268
Clinical presentation and treatment of gastrointestinal stromal tumors. 265
The role of histamine in doxorubicin and teniposide-induced cardiotoxicity in dog and mouse 261
Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy 260
TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma 259
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers 259
BRAFV600E Mutation and p27kip1 Expression in Papillary Carcinomas of the Thyroid ≤1 cm and Their Paired Lymph Node Metastases 259
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale 255
Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. 254
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. 253
Ductal lavage: a valid method of risk assessment and of early diagnosis in breast cancer. 253
A case of squamocellular uterine cervix carcinoma metastatic to the skin with enterocutaneous fistula. 253
Ductal lavage: a way of carefully tracing the breast-secreting duct 251
A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy 250
Emotional expression and coping style in female breast cancer. 249
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. 248
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. 247
Havep53 gene mutations and protein expression a different biological significance in colorectal cancer? 247
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. 245
Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. 245
EGFR genomic alterations in cancer: prognostic and predictive values 237
miR-20b Modulates VEGF Expression by Targeting HIF-1a and STAT3 in MCF-7 Breast Cancer Cells 234
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. 226
Antiproliferative Agents That Interfere with the Cell Cycle at the G(1)-->S Transition: Further Development and Characterization of a Small Library of Stilbene-Derived Compounds 220
Alexithymia and coping style in women going to visit in a breast cancer center. 219
Ductal Lavage: a valid method of risk assessment and of early diagnosis in breast cance 219
Effetti antileucemici di due stilbeni identificati in uve provenienti da vigneti affetti da peronospora e Botrytis cinerea 218
A phase II study of capecitabine oxaliplatin chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes 212
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer 209
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. 209
Effects of Propolis in cancer cells 208
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 207
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers 205
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. 205
Deep vein thrombosis and pulmonary embolism can be treated at home in cancer patients 203
ELF regimen in advanced gastrointestinal malignancies: An analysis of its clinical effectiveness and toxicity 203
Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation 200
Bortezomib: a new pro-apoptotic agent in cancer treatment. 197
A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma 197
Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. 195
Persistance of residual vein thrombosis after an episode of deep vein thrombosis of the lower limbs and the risk of new cancer and cardiovascular disease. 193
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? 190
Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer 189
ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER 186
A phase II study of Oxaliplatin Capecitabine chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes 184
Carcinoma squamocellulare del pene localmente avanzato: associazione tra risposta clinica e modificazione dei livelli di ferritina sierica. 183
Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. 183
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan 182
Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia 182
Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases 182
TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome 181
Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: Clinical implications 181
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer. Proceeding of ICACT Fifteenth International Congress on Anticancer Treatment February 9th 12th 2004, Paris accepted for oral presentation 180
Antitumor effects of the grape stilbenes resveratrol and piceatannol on multidrug and apoptosis resistant HL60 leukemia cells" 180
Cathepsin D, B and L circulating levels as prognostic markers of malignant progression 179
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. 176
Cardiotossicità e Cardioprotezione. 176
“Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer:the IGCS-COL multicentre, randomised, phase III study” 175
“Effects of combretastatin analogues on leukemic cell lines and normal hemopoietic cells” 175
Studio del pattern di distribuzione dell'Activina A nel siero di pazienti con metastasi ossee da carcinoma prostatico in trattamento con acido zoledronico 172
Gists eredo familiari e pediatrici: aspetti biomolecolari e clinici. 172
New potential circulating markers for the therapeutic monitoring of metastatic bone disease. 171
A phase 2 study of Oxaliplatin ( O ) – Capecitabine( C ) chemotherapy in metastatic breast cancer ( MBC ) patients pretreated with Anthracyclines and taxanes VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 171
DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study 170
A phase i-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma 169
Epirubicina (EPI ) e Docetaxel (DOC ) come chemioterapia primaria ( C P ) nel trattamento del carcinoma mammario localmente avanzato ( CMLA ). VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 167
Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. 167
A case report of inflammatory pseudotumor of the liver 167
Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding and phase II study 165
Alexithymia and copyng style in women going to visit in a breast cancer center 163
Haemopoietic effects of 7 alpha, 17 beta Dimethyltestosterone 161
Il polimorfismo S128R dell’E-Selectina: analisi genotipica e caratterizzazione funzionale nell’interazione cellule tumorale-endotelio. 160
Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). 160
DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: Results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study 160
Weekly Paclitaxel (T) and pegylated liposomal Doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 155
Studio di phase II: Docetaxel settimanale come seconda linea chemioterapia nel carcinoma prostatico avanzato. 154
Pegylated Liposomal Doxorubicin and weekly paclitaxel as first line treatment in metastatic breast cancer 154
Influenza del suolo sulla produzione di Ocratossina A lungo la filiera vitivinicola 154
The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final results 153
Cathepsin D in the malignant progression of neoplastic diseases 152
PML down-regulation in soft tissue sarcomas 151
Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience. 151
Totale 21.972
Categoria #
all - tutte 87.181
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.181


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021411 0 0 0 0 0 0 0 0 0 0 175 236
2021/20221.817 77 437 21 91 93 52 103 86 237 223 91 306
2022/20232.341 258 446 43 250 240 370 177 171 256 15 85 30
2023/20241.061 34 149 86 91 68 214 114 110 5 31 15 144
2024/20252.750 52 169 181 285 105 84 197 198 192 297 379 611
2025/202610.064 853 303 691 781 953 1.519 1.325 968 684 1.682 305 0
Totale 27.748